diasorinsp

At DiaSorin, we are at the forefront of biotechnological innovation, revolutionizing the field of in vitro diagnostics on a global scale. Our core mission is to engineer and deliver groundbreaking diagnostic solutions that empower clinicians and laboratory professionals to make critical health decisions with speed and accuracy. Through relentless research and development, we have pioneered advanced platforms in both immunodiagnostics and molecular diagnostics, establishing ourselves as specialists in identifying and managing a wide spectrum of medical conditions. Our proprietary LIAISON® family of fully automated analyzers, which utilize advanced Chemiluminescence (CLIA) technology, represents a paradigm shift in laboratory workflow, offering unparalleled efficiency, reliability, and a comprehensive menu of specialty tests for infectious diseases, endocrinology, oncology, and more.

Our commitment to innovation extends into the rapidly evolving world of molecular diagnostics. Following the strategic acquisition of Luminex Corporation, we have integrated the powerful xMAP® multiplexing technology into our portfolio, enabling the simultaneous analysis of multiple targets from a single sample. This synergy has propelled our capabilities, allowing us to develop sophisticated assays for complex genetic and infectious disease testing. From the Simplexa™ real-time PCR technology to the Verigene® system for rapid microbial identification, our technological arsenal is designed to address the most pressing diagnostic challenges. By developing these vertically integrated systems, from reagent kits to analytical instruments and software, DiaSorin is not just participating in the diagnostics market; we are actively shaping its future, providing the tools necessary for earlier disease detection, improved patient outcomes, and a healthier world.